Brought to you by 
Immatics raises €53.8mm through Series C round
17 Oct 2013
Executive Summary
Immatics biotechnologies GMBH (therapeutic cancer vaccines) raised €53.8mm ($70.4mm) through its Series C round. Over half of the money came from returning investors including dievini Hopp Biotech Holding (now immatics' largest shareholder), Wellington Partners, and others, with additional participation from new buyers AT Impf GMBH and funds advised by MIG. Proceeds will be used to initiate Phase III renal cell carcinoma trials with immatics' lead cancer vaccine IMA901. Including the Series C round, the ten-year-old company has now raised over €100mm.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immatics raises €53.8mm through Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice